EXCIVA - Trademark Details
Status: 814 - SU - Response After Non-Final Action - Entered
Image for trademark with serial number 87195766
Serial Number
87195766
Word Mark
EXCIVA
Status
814 - SU - Response After Non-Final Action - Entered
Status Date
2022-01-21
Filing Date
2016-10-06
Mark Drawing
4000 - Standard character mark Typeset
Published for Opposition Date
2017-09-19
Law Office Assigned Location Code
L30
Employee Name
HARMON, RAYMOND E
Statements
Goods and Services
Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the prevention of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, elixirs for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Preparations for the suppression of hormones; Preparations for the treatment of asthma; Preparations for the treatment of burns; Preparations for treating colds; Preparations in the form of granules and liquids for controlling and removing moss; Preparations in the form of powders for controlling and removing moss; Preparations to destroy mildew; Preparations to prevent chewing or biting by animals; Preparations to prevent nail-biting and thumb-sucking; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders
Translation of Words in Mark
The wording EXCIVA has no meaning.
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
005, 006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2016-10-13
Primary Code
005
First Use Anywhere Date
2018-07-02
First Use In Commerce Date
2018-07-02
Current Trademark Owners
Party Name
Party Type
21 - 1st New Owner After Publication
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Party Type
21 - 1st New Owner After Publication
Address
Please log in with your Justia account to see this address.
Party Type
20 - Owner at Publication
Address
Please log in with your Justia account to see this address.
Party Type
10 - Original Applicant
Address
Please log in with your Justia account to see this address.
Correspondences
Name
SREENIVASARAO VEPACHEDU
Address
Please log in with your Justia account to see this address.
Trademark Events
Event DateEvent Description
2016-10-10NEW APPLICATION ENTERED IN TRAM
2016-10-13NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2017-01-13ASSIGNED TO EXAMINER
2017-01-14NON-FINAL ACTION WRITTEN
2017-01-14NON-FINAL ACTION E-MAILED
2017-01-14NOTIFICATION OF NON-FINAL ACTION E-MAILED
2017-04-27TEAS RESPONSE TO OFFICE ACTION RECEIVED
2017-04-27CORRESPONDENCE RECEIVED IN LAW OFFICE
2017-04-27TEAS/EMAIL CORRESPONDENCE ENTERED
2017-05-01FINAL REFUSAL WRITTEN
2017-05-01FINAL REFUSAL E-MAILED
2017-05-01NOTIFICATION OF FINAL REFUSAL EMAILED
2017-05-26TEAS CHANGE OF CORRESPONDENCE RECEIVED
2017-06-11TEAS REQUEST FOR RECONSIDERATION RECEIVED
2017-07-18ASSIGNED TO LIE
2017-07-24CORRESPONDENCE RECEIVED IN LAW OFFICE
2017-07-24TEAS/EMAIL CORRESPONDENCE ENTERED
2017-08-12APPROVED FOR PUB - PRINCIPAL REGISTER
2017-08-30NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2017-09-19PUBLISHED FOR OPPOSITION
2017-09-19OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2017-09-26TEAS CHANGE OF CORRESPONDENCE RECEIVED
2017-09-27TEAS CHANGE OF CORRESPONDENCE RECEIVED
2017-10-17EXTENSION OF TIME TO OPPOSE RECEIVED
2018-01-17OPPOSITION INSTITUTED NO. 999999
2018-04-03TEAS CHANGE OF CORRESPONDENCE RECEIVED
2019-08-07ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
2020-07-05TEAS CHANGE OF OWNER ADDRESS RECEIVED
2020-07-05TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
2020-07-05ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
2020-07-05TEAS CHANGE OF CORRESPONDENCE RECEIVED
2020-07-05APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
2020-07-29ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
2021-03-25OPPOSITION DISMISSED NO. 999999
2021-03-29ASSIGNED TO EXAMINER
2021-03-29BOARD DECISION COUNTERCLAIM DENIED
2021-03-29OPPOSITION TERMINATED NO. 999999
2021-03-29TTAB RELEASE CASE TO TRADEMARKS
2021-05-11NOA E-MAILED - SOU REQUIRED FROM APPLICANT
2021-08-25TEAS STATEMENT OF USE RECEIVED
2021-08-28CASE ASSIGNED TO INTENT TO USE PARALEGAL
2021-08-28ITU OFFICE ACTION ISSUED FOR STATEMENT OF USE
2021-08-28TEAS POST PUBLICATION AMENDMENT RECEIVED
2021-08-31CASE ASSIGNED TO INTENT TO USE PARALEGAL
2021-08-25USE AMENDMENT FILED
2021-08-31USE AFFIDAVIT FAILED FORMALITIES
2021-08-31CASE ASSIGNED TO INTENT TO USE PARALEGAL
2021-08-31TEAS STATEMENT OF USE RECEIVED
2021-08-31IU INFORMAL RESPONSE RECEIVED
2021-09-14STATEMENT OF USE PROCESSING COMPLETE
2021-10-07SU - NON-FINAL ACTION - WRITTEN
2021-10-07NON-FINAL ACTION E-MAILED
2021-10-07NOTIFICATION OF NON-FINAL ACTION E-MAILED
2022-01-20TEAS RESPONSE TO OFFICE ACTION RECEIVED
2022-01-20CORRESPONDENCE RECEIVED IN LAW OFFICE
2022-01-21TEAS/EMAIL CORRESPONDENCE ENTERED